Child in Liverpool dies after contracting measles
A statement from the Alder Hey Children's NHS Foundation Trust said: 'To respect patient confidentiality, we can't comment on individual cases.
'We are concerned about the increasing number of children and young people who are contracting measles. Measles is a highly contagious viral illness which can cause children to be seriously unwell, requiring hospital treatment, and in rare cases, death.
'The number of children being treated at Alder Hey for effects and complications of measles is increasing (we have treated 17 since June).
'We treat children with a range of conditions and illnesses in our hospital, including those with compromised immunity due to other health issues, making them more susceptible to infections, including measles.
'We can prevent people, including children, from contracting measles through vaccination. Please protect yourself and vulnerable children and young people by ensuring you are fully vaccinated.'
The child is believed to be the second to succumb to an acute measles infection in Britain this decade.
It comes after a Royal College of Paediatrics and Child Health (RCPCH) report released earlier this month determined uptake of vaccines in the UK has stalled over the last decade and is, in many cases, declining.
None of the routine childhood vaccinations have met the target for 95% coverage since 2021, meaning youngsters are at risk of catching illnesses such as measles, meningitis and whooping cough.
The report said while some families are hesitant to vaccinate due to fears about the jabs, many face issues that could be resolved with more support, including difficulties booking and attending appointments and a lack of continuity of NHS care, with many parents seeing a different GP or clinician at each visit.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Independent
41 minutes ago
- The Independent
Warning issued to patients after using weight-loss jabs
Health chiefs have raised concerns about patients regaining weight after stopping popular weight-loss drugs such as Wegovy and Mounjaro, calling for robust support to prevent them from piling on the pounds again. The National Institute for Health and Care Excellence (Nice), the UK's health watchdog, highlighted research indicating that many individuals regain weight if not adequately supported after ceasing treatment. Nice stressed that those coming off the drugs should be offered "structured advice and follow-up support" to mitigate weight gain. This guidance specifically applies to individuals receiving these treatments through the NHS. However, an estimated 1.5 million people in the UK are currently using weight-loss injections, with the vast majority paying privately. These individuals will not be eligible for NHS support once their treatment concludes. Over the next three years, approximately 240,000 people deemed to have the "greatest need" are anticipated to receive Mounjaro, also known as tirzepatide, via the NHS. The new 'quality standard' from Nice says that NHS patients should be monitored for at least a year after they complete treatment, and extra support should be offered if needed. It emphasises building 'long-term behavioural habits, use self-monitoring tools, and draw on wider support – from online communities to family-led interventions and local activities'. This standard, a type of guidance for the health services in England and Wales, sets out expectations for health providers including how they should support patients. 'Successful weight management doesn't end when medication stops or when someone completes a behavioural programme,' said Professor Jonathan Benger, deputy chief executive and chief medical officer at Nice. 'We know that the transition period after treatment is crucial, and people need structured support to maintain the positive changes they've made. 'This new standard makes sure services provide that vital continuity of care, and it supports the NHS 10 Year Plan to shift from a 'sickness service' to a genuine health service focused on prevention.' Dr Rebecca Payne, chair of Nice's Quality Standards Advisory Committee, added: 'Weight management is a long-term journey, not a short-term fix. 'The evidence is clear that advice and support for maintaining weight after stopping medicines or completing behavioural interventions can help prevent weight regain and enable people to experience lasting benefits. 'We've seen excellent examples of services that already provide comprehensive discharge planning and ongoing support. 'This quality standard will help ensure all healthcare providers adopt these best practices, giving every person the best chance of maintaining their weight management success over the long term. 'This standard ensures healthcare services are equipped to provide that essential ongoing support.' Commenting, Henry Gregg, chief executive of the National Pharmacy Association, said: ' Pharmacies take their responsibilities seriously to provide full wrap around support to patients trying to achieve a healthy weight. 'We know that although medication can be effective in speeding up weight loss in some people, it is not a silver bullet and patients need to make long term lifestyle changes to make their weight loss sustainable. 'The current NHS roll out of weight loss treatment is very small, with only a handful of patients receiving it and it will continue to be the case that the vast majority of eligible patients will be seen by their pharmacy.' Professor Kamila Hawthorne, chairwoman of the Royal College of GPs, said: 'There is no one-size-fits-all approach to tackling obesity – what works for one patient will likely not work for another and, as with any medication, weight-loss drugs do not come without risk. 'It's also the case that patients will likely need support to sustain their weight loss once they stop taking the medication. As such, this is important and sensible guidance from Nice. 'As a college, we've been clear that whilst weight loss medications have significant potential benefits for patients who are struggling to lose weight, they mustn't be seen as a 'silver bullet' and ensuring access to sufficient 'wraparound' services – particularly for when patients come off their medication – will be key to optimal health outcomes.'
The Independent
41 minutes ago
- The Independent
Urgent warning over virus dangerous to newborns as cases surge abroad
Health experts say the UK should brace for a surge in a potentially serious virus following a record number of cases in Australia. NHS officials said that the Australian winter is often a good predictor of how viruses will spread in England. In Australia, respiratory syncytial virus (RSV) cases have surged in recent months, and officials have said that cases have been steadily increasing in England since the start of 2025. NHS England has urged pregnant women to get the vaccine, which protects against RSV, in order to protect their newborn babies. The virus is a leading cause of death among babies and the main cause of hospital admissions for children. Kate Brintworth, chief midwifery officer for NHS England, said that while for most adults, RSV 'only causes mild, cold-like symptoms, for older adults and young children, it can lead to serious breathing problems that can end up in hospitalisation'. 'Getting vaccinated while pregnant is the best way to protect your baby from the moment they are born, and now is the time for mums to act, to make sure their babies are protected ahead of their first few months this winter, when there tends to be more bugs circulating.' Pregnant women can get the jab from 28 weeks of pregnancy onwards through their maternity services or GP surgery. Older adults aged 75-79 are also eligible for the jab, and NHS England will start inviting people to come forward in the next few weeks. Symptoms of an RSV infection NHS RSV is a common cause of coughs and colds, but some people have a high risk of getting seriously ill from the virus, including babies and adults over the age of 75. In babies, RSV is a common cause of a type of chest infection called bronchiolitis. Last week, the UK Health Security Agency published data showing the efficacy of the vaccine. It said that the jab for pregnant women can prevent 72 per cent of hospital admissions for their babies. And the vaccine is 82 per cent effective at preventing hospital admissions for RSV among older adults, UKHSA said.
Scottish Sun
41 minutes ago
- Scottish Sun
New ‘crucial' fat jabs guidance issued for the NHS – are you affected?
Hundreds of thousands of Brits take the injections JABS UPDATE New 'crucial' fat jabs guidance issued for the NHS – are you affected? Click to share on X/Twitter (Opens in new window) Click to share on Facebook (Opens in new window) FAT jabs are not a 'quick fix' and patients must be followed up for at least a year to keep the weight off, the NHS watchdog has warned. The National Institute for Health and Care Excellence (Nice) told clinics to offer more follow-up appointments and aftercare. Sign up for Scottish Sun newsletter Sign up 1 2RD5P46 photo of Mounjaro Weight Loss Pen Credit: Alamy More than 1.5million Brits are thought to be taking weight loss injections such as Wegovy and Mounjaro. Most are on private prescriptions where many do not receive help with diet and exercise alongside the medication. Studies suggest people start re-gaining weight within two months of stopping the jabs, and often put it all back on within two years. Professor Jonathan Benger, chief medical officer at Nice, said: 'Successful weight management doesn't end when medication stops or when someone completes a behavioural programme. 'The transition period after treatment is crucial. 'People need structured support to maintain the positive changes they've made. 'This new standard makes sure services provide that vital continuity of care.' Check-ups to prevent weight regain The standard issued to NHS clinics tells them how to look after patients taking weight loss injections. They must get action plans for staying healthy at home and at work, have regular check-ins and have community support available. Dr Rebecca Payne, head of standards at Nice, said: 'Weight management is a long-term journey, not a short-term fix. 'The evidence is clear that advice and support for maintaining weight after stopping medicines can help prevent weight regain.' Sun Health Explainer: Fat jabs Everything you need to know about fat jabs Weight loss jabs are all the rage as studies and patient stories reveal they help people shed flab at almost unbelievable rates, as well as appearing to reduce the risk of serious diseases. Wegovy – a modified version of type 2 diabetes drug Ozempic – and Mounjaro are the leading weight loss injections used in the UK. Wegovy, real name semaglutide, has been used on the NHS for years while Mounjaro (tirzepatide) is a newer and more powerful addition to the market. Mounjaro accounts for most private prescriptions for weight loss and is set to join Wegovy as an NHS staple this year. How do they work? The jabs work by suppressing your appetite, making you eat less so your body burns fat for energy instead and you lose weight. They do this my mimicking a hormone called GLP-1, which signals to the brain when the stomach is full, so the drugs are officially called GLP-1 receptor agonists. They slow down digestion and increase insulin production, lowering blood sugar, which is why they were first developed to treat type 2 diabetes in which patients' sugar levels are too high. Can I get them? NHS prescriptions of weight loss drugs, mainly Wegovy and an older version called Saxenda (chemical name liraglutide), are controlled through specialist weight loss clinics. Typically a patient will have to have a body mass index (BMI) of 30 or higher, classifying them as medically obese, and also have a weight-related health condition such as high blood pressure. GPs generally do not prescribe the drugs for weight loss. Private prescribers offer the jabs, most commonly Mounjaro, to anyone who is obese (BMI of 30+) or overweight (BMI 25-30) with a weight-related health risk. Private pharmacies have been rapped for handing them out too easily and video calls or face-to-face appointments are now mandatory to check a patient is being truthful about their size and health. Are there any risks? Yes – side effects are common but most are relatively mild. Around half of people taking the drug experience gut issues, including sickness, bloating, acid reflux, constipation and diarrhoea. Dr Sarah Jarvis, GP and clinical consultant at said: 'One of the more uncommon side effects is severe acute pancreatitis, which is extremely painful and happens to one in 500 people.' Other uncommon side effects include altered taste, kidney problems, allergic reactions, gallbladder problems and hypoglycemia. Evidence has so far been inconclusive about whether the injections are damaging to patients' mental health. Figures obtained by The Sun show that, up to January 2025, 85 patient deaths in the UK were suspected to be linked to the medicines.
